Barr Ellison Solicitors – commercial property
Mid banner advertisement: BDO
ARM Innovation Hub
Advertisement: EY Mid banner
Advertisement: Simpsons Creative
Advertisement: Hewitsons mid banner
Advertisement: Kao Data Centre mid banner
RealVNC mid banner careers
Advertisement mid banner S-Tech 1
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Howard Group mid banner
Advertisement: Mogrify mid banner
Advertisement: RSM
Advertisement – Charles Stanley mid banner
21 January, 2021 - 23:25 By Tony Quested

Cambridge life science deals worth more than $50 billion over the last 12 calendar months

Deals valued at over £1 million in the East of England life science cluster in the last 12 calendar months totalled $50.371 billion – and that doesn’t include current and potential milestone payments, some of which are huge. 

A handful of milestone deals could ramp to $1bn in their own right. 

Fundraisings over $1m in the last 12 calendar months totalled just over a billion dollars – $1.113bn to be precise.

Acquisitions by local players of businesses based elsewhere massively out-muscled those negotiated by external parties for East of England companies. Local companies paid a total of $47bn for outside businesses with pipelines that strengthen their portfolios. 

In contrast acquisitions by external forces of Cambridge Cluster companies only totalled $2.258bn. Transaction value for a number of deals – in and out – were undisclosed so our totals are on the conservative side. 

Here’s the A to Z of all the major deals in the last year where valuations were identifiable even if they were not officially declared.

Acquisitions (in)
Alexion by AstraZeneca – $39bn (December 2020)
GRAIL by Illumina – $8bn (September 2020)
Marker Gene Technologies by Abcam – undisclosed (March 2020)

Acquisitions (out)
Horizon Discovery by PerkinElmer – $383m (October 2020)
KaNDy acquired by Bayer – $425m upfront with potential milestones up to $450m (August 2020)
Kymab by Sanofi – $1.45bn (January 2021)
Nanna Therapeutics by Astellas – £12m (June 2020).

Fundraisings ($1m+)
Abcam – $180m Nasdaq IPO (October 2020)
Abzena – $10m growth capital (August 2020)
Achilles Therapeutics – $71.94m Series C (November 2020)
Biofidelity – $12m (August 2020) – $41.5m (June 2020)
CellCentric – $33m private investment (October 2020)
Cerevance – $45m Series B (April 2020)
CN Bio Innovations – $9m scaleup funding (March 2020)
Congenica – $50m Series C (November 2020)
DefiniGEN – $4.43m funding round (November 2020)
Eagle Genomics – $9m scale-up funding (October 2020)
Endomag – $20m Series D (December 2020)
Evonetix – $30m Series B round (March 2020)
Freeline Therapeutics – $120m Series C (June 2020)
Horizon Discovery – $9.4m share placing (April 2020)
Immune Regulation – $53,4m Series B (Sept 2020)
Inivata – $25m investment by NeoGenomics (May 2020)
Inotec – $9.5m (February 2020)
Mission Therapeutics – $15m (July 2020)
Myricx Pharma – $6.14m funding (November 2020)
Nodthera – $55m Series B (June 2020)
PharmEnable – $2.45m (July 2020)
Qkine – $2m Series A (June 2020)
PolyProx Therapeutics – $1.36m seed funding (March 2020)
ReViral – $44m Series C (August 2020)
Sosei Heptares – $200m growth capital (July 2020)
Sosei Heptares – $48.4m from Medicxi (January 2020) – $6.85m Series A (January 2021)

Newsletter Subscription

Stay informed of the latest news and features